Navigation Links
Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011
Date:2/4/2011

to 40 patients and complete enrollment in the second half of calendar year 2011. We also plan to evaluate the safety of PCI-32765 in combination with several other common therapies in CLL and expect to begin enrollment in Q2 of calendar year 2011.-Diffuse Large B-Cell Lymphoma (DLBCL) Research has demonstrated that there are 2 distinct molecular subtypes in diffuse large B-cell lymphoma (ABC and GCB).  Activated B-cell, or ABC, is the poorer prognostic subtype and is characterized by activation of the B-cell receptor signaling pathway. Our Phase II program will evaluate 2 separate cohorts of patients with relapsed or refractory DLBCL who will receive single agent PCI-32765, those lymphoma patients with ABC and those with germinal center B-cell (GCB), the other molecular subtype. This study will evaluate safety and efficacy in approximately 60 patients. We anticipate that enrollment will begin during the first half of 2011. In parallel, we are also developing a Phase II safety trial combining PCI-32765 with chemotherapy in patients with relapsed or refractory DLBCL.


  • Abstract submitted to the 47th Annual Meeting of the American Society of Clinical Oncology (June 3 – 7, 2011) based on the Phase IB/II study data, evaluating safety and efficacy of administering the Btk Inhibitor, PCI-32765 as a single agent in CLL/SLL patients

  • Poster presentation at the 2011 GI Cancers Symposium of first in human Phase I results of Factor VIIa Inhibitor, PCI-27483 In the Phase I portion of the study, ascending repeated doses of PCI-27483 (dosages ranging from 0.8 to 1.5 mg/kg) were evaluated in 8 patients with pancreatic cancer receiving concomitant gemcitabine chemotherapy. Among the 5 patients in Phase I considered evaluable, all 5 had stable disease at week 12 and opted to extend treatment with PCI-27483. Three of the 5 patients have a progression free survival > / = 30 weeks (7 months). None
    '/>"/>


  • SOURCE Pharmacyclics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call
    2. Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
    3. Pharmacyclics, Inc. Rights Offering Oversubscribed
    4. Pharmacyclics Announces Subscription Price for Rights Offering
    5. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
    6. Pharmacyclics Files Registration Statement for Rights Offering
    7. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
    8. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
    9. Pharmacyclics Secures $5.0 Million in Debt Financing
    10. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
    11. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2014)... 2014 WriteResult, LLC – a premier ... again shown superiority when it comes to meeting the ... ePRO portion of their most recent study closeout on-time ... chose WriteResult’s digital writing platform to collect Patient Reported ... to complete drew data from a number of assessments ...
    (Date:8/26/2014)... An analysis by Replikins, Ltd. of Pubmed ... CoV virus strains has revealed extensive conservation and ... conservation and sharing of specific Replikin gene structures has ... as it did for the H5N1 influenza vaccine and ... been found to be effective (1,2). ...
    (Date:8/26/2014)... 2014 An analysis by Replikins, Ltd. of ... virus strains in Pubmed, has revealed extensive conservation and ... conservation and sharing of specific Replikin gene structures has ... as it did for the H5N1 influenza vaccine and ... been found to be effective (1,2). ...
    (Date:8/26/2014)... Vycom announced today that Modutek Corporation ... equipment, has selected its Flametec materials for a ... Beams (FRIB). This involved the creation of a ... Flametec PVC-C and Kytec PVDF material to clean superconducting ... linear accelerator (known as LINAC). , ...
    Breaking Biology Technology:A Perfect Record: WriteResult Maintains a 100% On-Time ePRO Record with Latest Irritable Bowel (IBS) Study Data Lock 2Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 2Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 3
    ... economic growth. , ,Six months ago I wrote ... Article Knocks the Rust Off State Manufacturing Outlook, that recounted ... an interview from a December edition of Barrons Magazine. In ... U.S. recovery in a quarter of a century and that ...
    ... Medical Systems has announced that its Vericis system ... terabytes of storage for digital cardiovascular images and other ... years worth of study results, which clinicians will be ... over the Web from outreach clinics. In such a ...
    ... so- called social networks, services such as LinkedIn, Spoke, and ... "I'm LinkedIn - Now What," and they have questioned the ... wasn't being critical, really; I just didn't see a clear ... in recent weeks, I've experienced one "a-ha" moment after another, ...
    Cached Biology Technology:Hey Willie, Wisconsin Manufacturing Doesnt Need an Aid Concert! 2Hey Willie, Wisconsin Manufacturing Doesnt Need an Aid Concert! 3Social networks and my big a-ha 2Social networks and my big a-ha 3Social networks and my big a-ha 4
    (Date:8/27/2014)... Now that health advocates, campaigns against trans-fats have ... additive, they,re taking aim at sugar for its ... and policymakers are still wrangling over the best ... according to an article in Chemical & ... of the American Chemical Society. , In the ...
    (Date:8/27/2014)... the main factors thought to be associated with ... are the age of the patient, mechanism of ... time, repair method, operation technique, and repair materials. ... repair of peripheral nerve injuries, there is no ... prognosis, and the dose-effect relationship of the predictors ...
    (Date:8/27/2014)... Complex of fires had consumed 24,939 acres of land ... as of eight hours ago. , Lightning strikes ... of the Klamath National Forest when a thunderstorm passed ... three of those fires are now 100 percent contained. ... their size at containment: Delta, 150 acres; Sutcliffe, 27 ...
    Breaking Biology News(10 mins):Happy Camp and July Fire Complexes in California 2
    ... Inherited diseases such as cystic fibrosis can be caused ... cells make proteins. David Bedwell, Ph.D., a professor in ... Microbiology, says scientists are now closer to producing drugs ... of genetic disease. Bedwell is a renowned researcher ...
    ... , ANAHEIM, CA: Can eating less be as simple as ... According to a team of researchers from Cornell University, it can. ... Calif., researchers led by Brian Wansink, director of the Cornell Food ... study of 78 adults. "We looked at whether serving ...
    ... of monitor lizard, a close relative of the Komodo dragon, ... by a professor at UC Santa Barbara and a researcher ... of Ecology, Evolution and Marine Biology at UCSB, and Valter ... Finland, are the first to describe the distinctive lizard, which ...
    Cached Biology News:Drug may treat cystic fibrosis, other diseases caused by 'nonsense mutations,' UAB researcher says 2New monitor lizard discovered in Indonesia 2